Literature DB >> 11586559

The role of antibiotics in the treatment of infectious diarrhea.

E C Oldfield1, M R Wallace.   

Abstract

Infectious diarrhea is a significant cause of morbidity and mortality and a common complaint in clinical practice. Routine empirical use of antibiotics for infectious diarrhea should be avoided because of the self-limited nature of most cases, the cost of antibiotics, and the potential to worsen the already significant problem of antibiotic resistance of enteric pathogens. For patients with severe invasive or prolonged diarrhea or who are at high risk of complications, such as the elderly, diabetics, cirrhotics, and immunocompromised patients, empirical treatment with a quinolone antibiotic for 3 to 5 days can be considered. Antibiotic treatment can be highly effective for Shigella, ETEC, and V. cholerae infections, and metronidazole is indicated for C. difficile colitis. The impact of antibiotics for other specific pathogens is modest, and antibiotic therapy should be reserved for the same group of patients who would be considered for empirical treatment. The most significant problem in the antibiotic treatment of infectious diarrhea is the progressive increase in resistance among enteric pathogens; only the prudent use of antimicrobials in all areas of daily practice can limit or delay the impact of this serious problem.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11586559     DOI: 10.1016/s0889-8553(05)70212-0

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  11 in total

1.  Treatment of diarrheal disease.

Authors: 
Journal:  Paediatr Child Health       Date:  2003-09       Impact factor: 2.253

2.  Options for treating resistant Shigella species infections in children.

Authors:  Sharon M Erdman; Elizabeth E Buckner; Janet F Hindler
Journal:  J Pediatr Pharmacol Ther       Date:  2008-01

3.  A single nucleotide change in mutY increases the emergence of antibiotic-resistant Campylobacter jejuni mutants.

Authors:  Lei Dai; Wayne T Muraoka; Zuowei Wu; Orhan Sahin; Qijing Zhang
Journal:  J Antimicrob Chemother       Date:  2015-07-13       Impact factor: 5.790

4.  Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli.

Authors:  T S Coster; M K Wolf; E R Hall; F J Cassels; D N Taylor; C T Liu; F C Trespalacios; A DeLorimier; D R Angleberger; C E McQueen
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

5.  Bacterial colitis.

Authors:  Harry T Papaconstantinou; J Scott Thomas
Journal:  Clin Colon Rectal Surg       Date:  2007-02

Review 6.  Diagnosis and treatment of bacterial diarrhea.

Authors:  James V Lawler; Mark R Wallace
Journal:  Curr Gastroenterol Rep       Date:  2003-08

7.  Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil.

Authors:  Leonidas A Bourikas; George Kolios; Vassilis Valatas; George Notas; Ioannis Drygiannakis; Iordanis Pelagiadis; Pinelopi Manousou; Stefanos Klironomos; Ioannis A Mouzas; Elias Kouroumalis
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

8.  When does overuse of antibiotics become a tragedy of the commons?

Authors:  Travis C Porco; Daozhou Gao; James C Scott; Eunha Shim; Wayne T Enanoria; Alison P Galvani; Thomas M Lietman
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

9.  A fluoroquinolone resistance associated mutation in gyrA Affects DNA supercoiling in Campylobacter jejuni.

Authors:  Jing Han; Yang Wang; Orhan Sahin; Zhangqi Shen; Baoqing Guo; Jianzhong Shen; Qijing Zhang
Journal:  Front Cell Infect Microbiol       Date:  2012-03-01       Impact factor: 5.293

10.  Key role of Mfd in the development of fluoroquinolone resistance in Campylobacter jejuni.

Authors:  Jing Han; Orhan Sahin; Yi-Wen Barton; Qijing Zhang
Journal:  PLoS Pathog       Date:  2008-06-06       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.